Exelixis Inc Restructuring Costs and Asset Impairment Charges
Exelixis Inc (EXEL) reported Restructuring Costs and Asset Impairment Charges of $0 for the 12-month period ending 2026-01-02, per its 10-K filed 2026-02-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:RestructuringCostsAndAssetImpairmentCharges · last filed 2026-02-10
- Exelixis Inc restructuring costs and asset impairment charges for the quarter ending 2026-01-02 was $0.00, a 100.00% decline year-over-year.
- Exelixis Inc restructuring costs and asset impairment charges for the quarter ending 2025-01-03 was $153.00K.
- Exelixis Inc restructuring costs and asset impairment charges for the quarter ending 2023-12-29 was $0.00.
- Exelixis Inc restructuring costs and asset impairment charges for the quarter ending 2013-12-31 was $0.00.
- Exelixis Inc restructuring costs and asset impairment charges for fiscal 2026 was $0.00, a 100.00% decline from fiscal 2025.
- Exelixis Inc restructuring costs and asset impairment charges for fiscal 2025 was $64.39M.
- Exelixis Inc restructuring costs and asset impairment charges for fiscal 2023 was $0.00.
- Exelixis Inc restructuring costs and asset impairment charges for fiscal 2022 was $0.00.
| Period end | Restructuring Costs and Asset Impairment Charges 3 month | Restructuring Costs and Asset Impairment Charges 6 month | Restructuring Costs and Asset Impairment Charges 9 month | Restructuring Costs and Asset Impairment Charges 12 month |
|---|---|---|---|---|
| 2026-01-02 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $0.00 10-K · filed 2026-02-10 | ||
| 2025-10-03 | $0.00 10-Q · filed 2025-11-04 | |||
| 2025-01-03 | $153.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $64.39M 10-K · filed 2026-02-10 | ||
| 2024-09-27 | $64.24M 10-Q · filed 2025-11-04 | |||
| 2023-12-29 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $0.00 10-K · filed 2026-02-10 | ||
| 2023-09-29 | $0.00 10-Q · filed 2024-10-29 | |||
| 2022-12-30 | $0.00 10-K · filed 2025-02-11 | |||
| 2015-09-30 | $0.00 10-Q · filed 2015-11-10 | |||
| 2014-09-30 | $667.00K 10-Q · filed 2015-11-10 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | $0.00 derived: sum of 2 quarters · filed 2014-11-04 | $0.00 derived: sum of 3 quarters · filed 2014-11-04 | $0.00 10-K · filed 2014-02-20 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $0.00 derived: sum of 2 quarters · filed 2014-11-04 | $0.00 10-Q · filed 2014-11-04 | -$63.00K derived: sum of 4 quarters · filed 2014-11-04 |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $0.00 10-Q · filed 2013-08-06 | -$63.00K derived: sum of 3 quarters · filed 2014-02-20 | -$25.00K derived: sum of 4 quarters · filed 2014-02-20 |
| 2013-03-31 | $0.00 10-Q · filed 2013-05-07 | -$63.00K derived: sum of 2 quarters · filed 2014-02-20 | -$25.00K derived: sum of 3 quarters · filed 2014-02-20 | -$9.00K derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-12-31 | -$63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | -$25.00K derived: sum of 2 quarters · filed 2014-02-20 | -$9.00K derived: sum of 3 quarters · filed 2014-02-20 | -$204.00K 10-K · filed 2014-02-20 |
| 2012-09-30 | $38.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30 | $54.00K derived: sum of 2 quarters · filed 2013-10-30 | -$141.00K 10-Q · filed 2013-10-30 | -$23.00K derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-06-30 | $16.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | -$179.00K 10-Q · filed 2013-08-06 | -$61.00K derived: sum of 3 quarters · filed 2014-02-20 | -$192.00K derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-03-31 | -$195.00K 10-Q · filed 2013-05-07 | -$77.00K derived: sum of 2 quarters · filed 2014-02-20 | -$208.00K derived: sum of 3 quarters · filed 2014-02-20 | $180.00K derived: sum of 4 quarters · filed 2014-02-20 |
| 2011-12-31 | $118.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | -$13.00K derived: sum of 2 quarters · filed 2014-02-20 | $375.00K derived: sum of 3 quarters · filed 2014-02-20 | $497.00K 10-K · filed 2014-02-20 |
| 2011-09-30 | -$131.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $257.00K derived: sum of 2 quarters · filed 2012-11-07 | $379.00K 10-Q · filed 2012-11-07 | $1.23M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-06-30 | $388.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02 | $510.00K 10-Q · filed 2012-08-02 | $1.36M derived: sum of 3 quarters · filed 2013-02-21 | $1.36M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-03-31 | $122.00K 10-Q · filed 2012-05-03 | $968.00K derived: sum of 2 quarters · filed 2013-02-21 | $968.00K derived: sum of 3 quarters · filed 2013-02-21 | |
| 2010-12-31 | $846.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $846.00K derived: sum of 2 quarters · filed 2013-02-21 | $3.33M 10-K · filed 2013-02-21 | |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $2.48M 10-Q · filed 2011-10-27 | ||
| 2010-06-30 | $2.48M 10-Q · filed 2011-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |